Mucoadhesive patch for the treatment of RAS (recurrent aphthous stomatitis -aphte).
| Reference number | |
| Coordinator | Mucocort AB |
| Funding from Vinnova | SEK 70 700 |
| Project duration | June 2020 - October 2021 |
| Status | Completed |
| Venture | Medtech4Health: Competence Enhancement in SME |
| Call | Medtech4Health: Skills enhancement in small businesses - 2020 |
Important results from the project
** Denna text är maskinöversatt ** The aim was to develop a final version of a "patch" for aphthae. This has now been achieved, and we will complete our biocompatibility studies according to ISO 10993. The biocomp studies will be completed by the turn of 2021. After this, we will submit an ethics application to the ethics committee and a proposal to the Medical Products Agency to conduct a clinical study. What we have not succeeded in achieving is a complete bio-company analysis. This is due to some complications with our suppliers and Corona. We have received major delays due to the situation.
Expected long term effects
We have now developed a patch with the properties required for an effective treatment that accelerates healing and has a quick pain relief. The outcome has been very positive in terms of size, simplicity with a good opportunity for high "compliance" for both children and adults. The product is fully biodegradable and doesn´t contains any pharmaceuticals.
Approach and implementation
Through our own development and in collaboration with other researchers, we have developed the patch to the form it is today through composition tests in labs and in-vitro tests. In addition, there has been a continuous regulatory adjustment to the new rules that apply. We work today with ISO 13485, ISO 10993 and ISO 14155.